GSK: promising new data in multiple myeloma
(CercleFinance.com) - GlaxoSmithKline today presented promising new data for the treatment of multiple myeloma, the second most common blood cancer in the United States.
In a study of 35 heavily pre-treated patients, GSK2857916 monotherapy demonstrated a 60% response rate and a median progression free survival of 7.9 months, the British drugmaker said.
The results were presented at the annual meeting of the American Society for Hematology (ASH).
Multiple myeloma is generally considered treatable, but not curable.
GSK places heavy emphasis on GSK2857916, which it considers as the leading asset of its emerging pipeline of oncology medicines.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In a study of 35 heavily pre-treated patients, GSK2857916 monotherapy demonstrated a 60% response rate and a median progression free survival of 7.9 months, the British drugmaker said.
The results were presented at the annual meeting of the American Society for Hematology (ASH).
Multiple myeloma is generally considered treatable, but not curable.
GSK places heavy emphasis on GSK2857916, which it considers as the leading asset of its emerging pipeline of oncology medicines.
Copyright (c) 2017 CercleFinance.com. All rights reserved.